Skip to content

Rehabilitation Based on Hybrid Neuroprosthesis

Rehabilitation Based on Hybrid Neuroprosthesis: Evaluation of the Feasibility, Functionality and Usability of the System in a Post-stroke Patient Population.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07270484
Acronym
ReHyb
Enrollment
24
Registered
2025-12-08
Start date
2024-02-12
Completion date
2024-05-24
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Stroke

Keywords

post stroke, Rehabilitation, Robobotics, Hybrid, Exoskeleton

Brief summary

The study is a pilot, multi-center, prospective, and open study to test feasibility, functionality and usability of a device defined as a hybrid neuroprosthesis.

Detailed description

The ReHyb project, being oriented towards the development of a hybrid, modular, flexible and patient-specific upper-body hybrid neuro-prosthesis, potentially able to maximize the training efficacy during hospital stay as well as home-based rehabilitation or assistance during Activities of Daily Living (ADL), offering at the same time a pleasant user experience, has led to the development and integration of different modules in an attempt to adapt to the specific conditions of different patients. This goal has oriented the Consortium toward a participatory design (PD) and an ethics-by-design approach (EbD) that has been applied all along the execution of the project. Under this perspective, two platforms have been developed and evaluated according to the following: \- Evaluation of platforms: The global evaluation of the ReHyb system and its two developed platforms, High Power Platform (HPP) and Low Power Platform (LPP). To meet this goal, a pilot, multicenter, prospective, and open study was defined to test feasibility, functionality and usability of the two platforms that constitute the hybrid neuro-prosthesis developed. A total of 24 post-stroke patients (12 per clinical site) were recruited during a time-span of 12 months for the evaluation of the ReHyb system. This number was considered sufficient for the statistical analysis to investigate the feasibility and usability of the platforms. Furthermore, the sample size is expected to allow for finding most of the usability problems. When evaluating the ReHyb platforms in full and in their different module combinations, the ReHyb project has incorporated two different hardware devices: a stationary high powered device (ReHyb-HP) and a portable spring-loaded device (ReHyb-SL), which are both integrated with FES support. The software components include the control algorithms of the platforms, a training environment (e.g., the Rehabilitations Gaming System (RGS), a desktop Virtual Reality (VR) setup with gamified protocols for motor and cognitive rehabilitation), and the Digital Twin (e.g., the level of task difficulty and the amount of support will be adapted to the capabilities of the user). The general scope of the studies herein presented is about evaluating the developed ReHyb System regarding its feasibility, functionality and usability rather than about evaluating any therapeutic effect of using the device. As a consequence, with a maximum duration of 3 weeks and five sessions of training per subject, the study participation is probably not long enough to expect therapeutic effects induced by the hybrid training. In fact, in previous studies, a minimum of four to seven weeks of intervention was required to detect significant clinical improvements in upper limb functions. The applied clinical investigation protocol (CIP) was the same for the two clinical rehabilitation centres namely: Schön Klinik (SK) and VALDUCE. Nevertheless, some minimal differences were registered between the two centres without major impact on the results obtained, but with interesting complementary information coming from some of the main stakeholders on the use of the new integrated devices. In particular, SK has included the evaluation made by healthcare operators and caregivers, who have been considered the closest stakeholders to patients involved in the study.

Interventions

DEVICEReHyb-HPP

Up to 7 sessions lasting approximately 60 minutes will be carried out, including dressing and undressing the exoskeleton and/or electrodes. At the end of the third and fifth training sessions, some questionnaires will be administered. At the end of each training session, the patient's adherence to the selected platform configuration will be reassessed and modified as appropriate to ensure the subject's comfort and, at the same time, to evaluate the platform's adaptability to the subject's specific conditions. Together with Functional electrical stimulation, patients received active assistance during predefined repetitive movements of the upper limb playing a single game.

DEVICEReHyb-LPP

Up to 7 sessions lasting approximately 60 minutes will be carried out, including dressing and undressing the exoskeleton and/or electrodes. At the end of the third and fifth training sessions, some questionnaires will be administered. At the end of each training session, the patient's adherence to the selected platform configuration will be reassessed and modified as appropriate to ensure the subject's comfort and, at the same time, to evaluate the platform's adaptability to the subject's specific conditions. Together with Functional electrical stimulation, patients received passive assistance only at the shoulder level, during unstructured movements of the upper limb playing games with adaptive difficulty.

Sponsors

Technical University of Munich
CollaboratorOTHER
Össur Iceland ehf
CollaboratorINDUSTRY
Imperial College London
CollaboratorOTHER
Technical University of Denmark
CollaboratorOTHER
Schoen Clinic Bad Aibling
CollaboratorOTHER
Radboud University, The Netherlands
CollaboratorUNKNOWN
Scuola Superiore Sant'Anna di Pisa
CollaboratorOTHER
IUVO S.r.l.
CollaboratorINDUSTRY
Tecnalia
CollaboratorUNKNOWN
Villa Beretta Rehabilitation Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

6 patients per platform in each clinical site were enrolled. This led to a total sample size of 24 patients. The 24 patients defined as the sample size was considered appropriate for feasibility evaluation since the system was composed by two different platforms related to the different needs patients may have according to their clinical conditions.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults (women or men aged ≥ 18 years) * with a diagnosis of stroke either hemorrhagic or ischemic * with a hemiparesis of the upper limb (0 ≤ MRC ≤ 4) * in sub-acute (up to six months after acute event) or chronic condition (more than 6 months from the acute event). * Able to sit upright for the duration of the test. * Subjects with a level of cognitive capacity that enables him/her to follow the instructions related to the performance of exercises.

Exclusion criteria

* Subjects with a high level of spasticity (Modified Ashworth Scale: In general \>3 except for motorized joints which may be \>2) * Pain in the affected upper limb (Numeric Rating Scale \> 4) * Severe psychiatric disorder * Permanent neurological symptoms present immediately before stroke * Physical conditions that can alter normal biomechanics (e.g., recent sprains or injuries, etc.) * Pregnant or nursing women * No written informed consent from the patient or the legal representative * Active implantable devices (e.g., pacemaker) * Unstable medical condition

Design outcomes

Primary

MeasureTime frameDescription
Feasibility scoreDay3 and Day5Feasibility score is assessed by means of Unified Theory of Acceptance and Use of Technology questionnaire (UTAUT, 1-7on a likert scale per each item),
UsabilityDay 6Perceived Usability of the device from the patients perspective. Assessed with System Usability Scale (SUS) scale questionnaire. The scale ranges from 0-100.
Number of adverse Eventsfrom enrollment to end of treatment (up to 2 weeks).Safety of the delivered treatment is assessed monitoring the number of Adverse Event (AE). The metric is the number of events.
FeasibiliyDay 3 and Day 5Feasibiliy is evaluated with the User Experience Questionnaire (UEQ, -3 to 3 on a likert scale per each item) - short.

Secondary

MeasureTime frameDescription
Assistive TorquesFrom enrollment to the end of treatment (up to two weeks)Functionality of the platform is assessed with performance of the designed assistive algorithms, and their correct functioning, namely average torques provided (measured in Nm) across sessions.
Assistance Stimulation currentsThroughout the delivered therapy (up to two weeks).Functionality of the platform is assessed with performance of the designed assistive algorithms, and their correct functioning, namely , average stimulation currents (measured in mA) across session.

Countries

Germany, Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026